Track Tempus AI, Inc. Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Tempus AI, Inc. Class A Common Stock TEM Open Tempus AI, Inc. Class A Common Stock in new tab

47.39 USD
P/E
41.79
EPS
-1.41
P/B
17.18
ROE
-89.48
Target Price
75.43 USD
Tempus AI, Inc. Class A Common Stock logo

Tempus AI, Inc. Class A Common Stock

🧾 Earnings Recap – Q3 2025

Tempus AI reported a strong Q3 2025, achieving robust growth in both Genomics and Data Licensing, culminating in the company’s first positive adjusted EBITDA.

  • Genomics volume surged 33% overall, with notable growth in Hereditary (37%) and Oncology (27%).
  • The Data Licensing segment grew 38%, adding $150 million in total contract value.
  • Achieved positive adjusted EBITDA for the first time, a significant milestone after 10 years, despite expenses from the Paige acquisition.
  • Growth is underpinned by improved sales efficiency and advancements in their integrated technology offerings.
  • Adjusted EBITDA for the full year is now expected to be slightly positive, even accounting for additional costs from acquisitions.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 12, 2026
P/E41.79
EPS-1.41
Book Value2.76
Price to Book17.18
Debt/Equity270.11
% Insiders39.112%
Growth
Revenue Growth0.83%
Estimates
Forward P/E-758.85
Forward EPS-0.06
Target Mean Price75.43

DCF Valuation

Tweak assumptions to recompute fair value for Tempus AI, Inc. Class A Common Stock (TEM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Tempus AI, Inc. Class A Common Stock Logo Tempus AI, Inc. Class A Common Stock Analysis (TEM)

United States Healthcare Official Website Stock

Is Tempus AI, Inc. Class A Common Stock a good investment? Tempus AI, Inc. Class A Common Stock (TEM) is currently trading at 47.39 USD. Market analysts have a consensus price target of 75.43 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 41.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Tempus AI, Inc. Class A Common Stock is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is -0.06.

Investor FAQ

Does Tempus AI, Inc. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Tempus AI, Inc. Class A Common Stock?

Tempus AI, Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -1.41.

Company Profile

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Exchange Ticker
None TEM

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion